Raphael Pharmaceutical (RAPH) Operating Income (2020 - 2024)
Raphael Pharmaceutical (RAPH) posted Operating Income of -$394000.0 for Q4 2024, down 23.51% sequentially from -$319000.0 in Q3 2024, and down 394.03% YoY from $134000.0 in Q1 2024.
Raphael Pharmaceutical (RAPH) Operating Income (2020 - 2024) Analysis & Trends
Raphael Pharmaceutical has reported Operating Income for 5 years, with the latest figure at -$394000.0 in Q4 2024.
- Quarterly Operating Income fell 394.03% year-over-year to -$394000.0 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was -$1.5 million (down 18.63% YoY) and the FY2025 annual result came in at -$1.2 million, up 17.5% from the prior year.
- Operating Income fell to -$394000.0 in Q4 2024 per RAPH's latest filing, from -$319000.0 in the prior quarter.
- Over five years, Operating Income peaked at $134000.0 in Q4 2023 and troughed at -$1.4 million in Q3 2022.
- A 5-year average of -$467882.4 and a median of -$394000.0 in 2024 frame the typical range for Operating Income.
- The sharpest annual moves came in 2023 and 2024: Operating Income soared 112.14% in 2023, then sank 394.03% in 2024.
- Over 5 years, Operating Income stood at -$227000.0 in 2020, then tumbled by 152.86% to -$574000.0 in 2021, then slumped by 92.33% to -$1.1 million in 2022, then soared by 112.14% to $134000.0 in 2023, then tumbled by 394.03% to -$394000.0 in 2024.
- According to Business Quant data, Operating Income over the past three periods registered -$394000.0, -$319000.0, and -$249000.0 for Q4 2024, Q3 2024, and Q2 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.07 Bn | 43.10 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.42 Bn | 39.76 Bn | 2.15 Bn | -231.00 Mn |
| 3 | Zoetis | 31.86 Bn | 30.18 Bn | 1.05 Bn | 837.00 Mn |
| 4 | Takeda Pharmaceutical | 28.77 Bn | 22.98 Bn | 5.10 Bn | 1.26 Bn |
| 5 | United Therapeutics | 22.29 Bn | 19.63 Bn | 683.80 Mn | 330.80 Mn |
| 6 | Viatris | 18.78 Bn | 17.89 Bn | 1.46 Bn | 6.30 Mn |
| 7 | Neurocrine Biosciences | 15.66 Bn | 15.27 Bn | 935.80 Mn | 151.50 Mn |
| 8 | Elanco Animal Health | 11.91 Bn | 11.38 Bn | 798.00 Mn | 248.00 Mn |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 10.00 Bn | - | - |
| 10 | Raphael Pharmaceutical | 28.25 Mn | 28.25 Mn | - | -199,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -394,000.00 |
| Sep 30, 2024 | -319,000.00 |
| Jun 30, 2024 | -249,000.00 |
| Mar 31, 2024 | -547,000.00 |
| Dec 31, 2023 | 134,000.00 |
| Sep 30, 2023 | -729,000.00 |
| Jun 30, 2023 | -419,000.00 |
| Mar 31, 2023 | -258,000.00 |
| Dec 31, 2022 | -1.10 Mn |
| Sep 30, 2022 | -1.43 Mn |
| Jun 30, 2022 | -612,000.00 |
| Mar 31, 2022 | -175,000.00 |
| Dec 31, 2021 | -574,000.00 |
| Sep 30, 2021 | -418,000.00 |
| Jun 30, 2021 | -385,000.00 |
| Mar 31, 2021 | -252,000.00 |
| Dec 31, 2020 | -227,000.00 |